Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation

New preclinical data on the pathogenic role of C1q on photoreceptor synapse elimination and the protection of photoreceptors and their function from C1q blockade in GA will be featured as a poster presentation

BRISBANE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the Company will have two presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 5-9, 2024 in Seattle, Washington. Additional Phase 2 clinical results of ANX007 from the ARCHER trial in geographic atrophy (GA), including further analyses of visual acuity and photoreceptor preservation, will be presented as an oral presentation. Also, new preclinical data on the role of C1q in the pathogenic elimination of photoreceptor synapses and protection of photoreceptors and their function with C1q blockade in GA will be presented as a poster presentation.

Details of the presentations are as follows:

Oral Presentation: “Protection Against Vision Loss by ANX007: Results from the Phase 2 ARCHER Clinical Trial”

• Abstract #: 2791
• Session: AMD; Clinical research II
• Presenter: Dr. David S. Boyer, Retina-Vitreous Associates Medical Group, California
• Date/Time: Tuesday, May 7, 2024, 9:15 – 9:30 a.m. PT
• Location: Seattle Convention Center, Arch Building Room 612
  

Poster Presentation: “C1q inhibition protects photoreceptor synapses and preserves retinal function in a preclinical model of photoreceptor degeneration”

• Abstract #: 3944
• Session: Neuroprotection in the retina
• Presenter: Dr. Alessia Tassoni, Associate Director at Annexon Biosciences
• Date/Time: Tuesday, May 7, 2024, 3:30 – 5:15 p.m. PT
• Location: Seattle Convention Center, Arch Building, Exhibit Hall, Posterboard #A0463
  

Additional presentation details and abstracts are available on the ARVO 2024 website here.

About ANX007 and Phase 2 ARCHER Trial
ANX007 is a fragment antigen-binding (fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway, and a key driver of neurodegeneration. In GA, C1q binds to photoreceptor synapses early in the disease process, causing aberrant activation of the classical pathway with synapse loss, inflammation and neuronal damage that results in vision loss. Intravitreal administration of ANX007 fully stops C1q and classical pathway activation, and in animal models, its murine analog protects photoreceptor synapses and cells essential for vision. ANX007 is the first therapeutic candidate for the treatment of GA to receive PRIME designation in the EU, which provides early and proactive support to developers of promising medicines that may offer a major therapeutic advantage over existing treatments or benefit to patients without treatment options.